Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19 CHARLOTTESVILLE, Va., Aug. 25, 2020 /PRNewswire/ — Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced today by Biovista, an AI-driven bioscience firm that … Read More
News
Repositioning Safety
There is an urgent need for the healthcare industry to reposition safety: that is to change how the ability to discover, possess information about and act on predicted Adverse Drug Reactions (ADR) is perceived and treated by pharma companies, the regulator and other stakeholders. To date drug testing has been biased toward minimizing “Type I” … Read More
Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19
CHARLOTTESVILLE, Va., April 22, 2020 /PRNewswire/ — Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds — to counter key symptoms of COVID-19. “Drug AI helps find that needle in the haystack, and we are optimistic that we have found four … Read More
Business Development Agent in Japan
Biovista is pleased to announce the appointment of a Business Development Agent in Japan. Based in Tokyo, our BD Agent will serve Biovista customers and collaborators throughout Japan. Our agent will focus on Biovista’s new therapy development services and will serve as the main contact point for our Japanese customers. Additionally, our Agent will support … Read More
High Throughput Layout and Copy Paste
The latest version of Biovista Vizit introduces two much requested features: A new High Throughput Layout, and A new Copy/Paste mechanism to transfer named Entities in and out of Vizit. Here’s a quick rundown of the new features: High Throughput Layout Biovista Vizit is frequently used for systematic exploration of a biomedical domain. For example, … Read More